Their focus is on the proportion of TIICs and clinical characteristics to assess the risk of PCa recurrence18, the relationship between immune cell infiltration and TMB score19, use ssGSEA to measure immune infiltration20, potential drug target for CRPC, and we screened the same biomarker NPY, which also proved the reliability of our model21. This evidence concerns the gene NPY and posterior cortical atrophy.